$ News

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Sector Update: Health Care Stocks Advance Tuesday Afternoon

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Supernus makes depression drug play with $795m Sage buyout

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes

Sage, following Setbacks, to sell to Supernus for $561M

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

Sage Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Sage Therapeutics Announces R&D Leadership Transition

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025